Sage drops a pair of late-stage tests for Bio­gen-part­nered de­pres­sion drug, rais­ing the stakes on a fi­nal tri­al

When Sage Ther­a­peu­tics’ star ex­per­i­men­tal de­pres­sion drug, zu­ra­nolone, failed the cru­cial MOUN­TAIN study, the biotech slammed the brakes on two oth­er piv­otal tri­als in or­der …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER